RecruitingPhase IEN originalLung cancerMetastatic / advanced

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well it works in determining treatment response for patients with stage IV non-small cell lung cancer (NSCLC) already receiving pembrolizumab. 64Cu-DOTA-pembrolizumab consists of a monoclonal antibody, pembrolizumab, that binds to a protein called PD-1 that is expressed on tumor cells. PET scans can then visualize the tumor cells using 64Cu, a radioactive substance. 64Cu-DOTA-pembrolizumab PET scans may be safe and useful to doctors in telling the difference between tumors that are still growing and areas that are not growing in patients with stage IV NSCLC receiving pembrolizumab treatment.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek co najmniej 18 lat
  • Potwierdzony zaawansowany rak płuc (stadium IV)
  • Pacjent obecnie leczony pembrolizumabem
  • Kwalifikacja do radioterapii stereotaktycznej
  • Liczba neutrofili w normie (≥1000/mm³)
  • Liczba płytek krwi wystarczająca (≥50000/mm³)
  • Funkcja nerek w normie (oczyszczanie kreatyniny ≥30 mL/min)
  • Dla kobiet w wieku rozrodczym: negatywny test ciąży

✗ Disqualifies

  • Plan przerwania leczenia pembrolizumabem w momencie rozpoczęcia badania
  • Szczepienie żywymi szczepionkami w ciągu 4 tygodni przed badaniem (z wyjątkiem szczepionek na COVID-19 i grypę)

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 12, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

City of Hope Medical Center

Duarte, United States

Trial contact

Sagus Sampath

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.